Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM)
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Multiple Myeloma
Спонсор: Landspitali
Налично на:
БГ
Обобщение
Trial status: Authorised
Clinical response by IMWG, Clinical outcomes by IMWG, Safety, Correlation with correlative and clinical outcomes
Primary: Proportion of participants diagnosed with intermediate or high risk SMM that have MRD negativity three year from study enrollment
Описание
Clinical response by IMWG, Clinical outcomes by IMWG, Safety, Correlation with correlative and clinical outcomes
Кой може да участва
Age group: 18-64 years
Gender: Female, Male
Target enrollment: 80 participants
БГ
EN